[Treatment of PCM1-JAK2-positive myeloproliferative neoplasm with eosinophilia using ruxolitinib: a case report].
作者信息
Song Y, Zhang Y R, Han Y, Wang Y, Li Y Q, Chai Y, Zeng P Y, Yue L L, Wu C Y
机构信息
Department of Hematology, the Second Hospital of Lanzhou University, Lanzhou 730000, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2021 Aug 14;42(8):690. doi: 10.3760/cma.j.issn.0253-2727.2021.08.015.
Abstract
摘要
相似文献
1
[Treatment of PCM1-JAK2-positive myeloproliferative neoplasm with eosinophilia using ruxolitinib: a case report].[使用芦可替尼治疗PCM1-JAK2阳性嗜酸性粒细胞增多性骨髓增殖性肿瘤：1例报告]
Zhonghua Xue Ye Xue Za Zhi. 2021 Aug 14;42(8):690. doi: 10.3760/cma.j.issn.0253-2727.2021.08.015.
2
Sustained Response to Ruxolitinib of Eosinophilia-Associated Myeloproliferative Neoplasm with Translocation t(8;9)(p21;p24).伴嗜酸粒细胞增多的骨髓增生性肿瘤伴 t(8;9)(p21;p24)易位患者对芦可替尼的持续缓解。
Acta Haematol. 2023;146(5):397-400. doi: 10.1159/000510281. Epub 2023 Aug 10.
3
TLE3 Is a Novel Fusion Partner of JAK2 in Myeloid/Lymphoid Neoplasm With Eosinophilia Responding to JAK2 Inhibition.TLE3 是一种新型融合伙伴，存在于伴有嗜酸性粒细胞增多的髓系/淋巴系肿瘤中，对 JAK2 抑制有反应。
Genes Chromosomes Cancer. 2024 Aug;63(8):e23261. doi: 10.1002/gcc.23261.
4
Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.芦可替尼在伴有PCM1-JAK2融合基因的髓系肿瘤中的疗效。
Ann Hematol. 2015 Nov;94(11):1927-8. doi: 10.1007/s00277-015-2451-7. Epub 2015 Jul 23.
5
Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib.在接受鲁索替尼治疗的JAK2 V617F骨髓增殖性肿瘤中BCR-ABL克隆的扩增
Ann Hematol. 2016 Jan;95(2):349-50. doi: 10.1007/s00277-015-2518-5. Epub 2015 Oct 13.
6
Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of with erythroblastic sarcoma: a case report and literature review.与嗜酸性粒细胞增多及重排相关的髓系/淋系肿瘤伴成红细胞肉瘤：一例报告及文献复习
Haematologica. 2023 Dec 1;108(12):3506-3510. doi: 10.3324/haematol.2022.282228.
7
Dynamics of JAK2 V617F allele burden of CD34+ haematopoietic progenitor cells in patients treated with ruxolitinib.芦可替尼治疗患者中CD34+造血祖细胞JAK2 V617F等位基因负荷的动态变化
Br J Haematol. 2016 Feb;172(4):639-42. doi: 10.1111/bjh.13535. Epub 2015 Jun 26.
8
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements.芦可替尼作为 JAK2 重排患者潜在的靶向治疗药物。
Haematologica. 2013 Mar;98(3):404-8. doi: 10.3324/haematol.2012.067959. Epub 2012 Aug 8.
9
BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia.伴有嗜酸性粒细胞增多的骨髓增殖性肿瘤中的BCR-JAK2融合
Cancer Genet. 2016 May;209(5):223-8. doi: 10.1016/j.cancergen.2016.03.002. Epub 2016 Apr 6.
10
Myeloid neoplasm with eosinophilia and associated with acute promyelocytic leukemia with .伴有嗜酸性粒细胞增多且与急性早幼粒细胞白血病相关的髓系肿瘤
Leuk Lymphoma. 2019 Sep;60(9):2299-2303. doi: 10.1080/10428194.2019.1581927. Epub 2019 Feb 26.
Zotero 插件